Simultaneous monitoring of cytomegalovirus-specific antibody and T-cell levels in seropositive heart transplant recipients

Journal of Clinical Immunology

Volumn 32, Issue 4, 2012, Pages 809-819

  Carbone, Javier ^a   Lanio, Nallibe ^a   Gallego, Antonio ^a   Kern, Florian ^b,c   Navarro, Joaquin ^a   Muñoz, Patricia ^a   Alonso, Roberto ^a   Catalán, Pilar ^a   Fernández Yáñez, Juan ^a   Palomo, Jesús ^a   Ruiz, Manuel ^a   Fernández Cruz, Eduardo ^a   Sarmiento, Elizabeth ^a,c  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Anti cytomegalovirus antibodies; CD8 specific T cell response; Cytomegalovirus; Heart transplantation; Immune monitoring; Infection

Indexed keywords

CEFAZOLIN; COTRIMOXAZOLE; CYCLOSPORIN; CYTOMEGALOVIRUS ANTIBODY; CYTOMEGALOVIRUS ANTIGEN PP65; DACLIZUMAB; GAMMA INTERFERON; GANCICLOVIR; IMMEDIATE EARLY PROTEIN; IMMEDIATE EARLY PROTEIN 1; IMMUNOGLOBULIN G ANTIBODY; ITRACONAZOLE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NORFLOXACIN; NYSTATIN; PREDNISONE; TACROLIMUS; UNCLASSIFIED DRUG; VALGANCICLOVIR;

ACINETOBACTER INFECTION; ADULT; ANTIBODY TITER; ARTICLE; BACTERIAL INFECTION; CANDIDIASIS; CARDIAC GRAFT REJECTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT RECIPIENT; HEART TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; INFECTION RISK; INVASIVE ASPERGILLOSIS; MALE; MYCOSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS INFECTION;

EID: 84863990413     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-012-9670-7     Document Type: Article

References (36)

1. Gurgui M, Munoz P. Infection in heart transplantation. Enferm Infecc Microbiol Clin. 2007;25(9):587-97.
2. Pérez-Sola MJ, Castón JJ, Solana R, Rivero A, Torre-Cisneros J. Indirect effects of cytomegalovirus infection in solid organ transplant recipients. Enferm Infecc Microbiol Clin. 2008;26(1):38-47. (Pubitemid 351159052)
3. Avery RK. Prevention and treatment of cytomegalovirus infection and disease in heart transplant recipients. Curr Opin Cardiol. 1998;13(2):122-9. (Pubitemid 28154319)
4. Potena L, Holweg CT, Vana ML, et al. Frequent occult infection with Cytomegalovirus in cardiac transplant recipients despite antiviral prophylaxis. J Clin Microbiol. 2007;45(6):1804-10. (Pubitemid 46933911)
5. Kijpittayarit-Arthurs S, Eid AJ, Kremers WK, et al. Clinical features and outcomes of delayed-onset primary cytomegalovirus disease in cardiac transplant recipients. J Heart Lung Transplant. 2007;26(10):1019-24. (Pubitemid 47500146)
6. Li F, Kenyon KW, Kirby KA, et al. Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients. Clin Infect Dis. 2007;45(4):439-47. (Pubitemid 47204459)
7. Baldanti F, Lilleri D, Gerna G. Monitoring human cytomegalovirus infection in transplant recipients. J Clin Virol. 2008;41(3):237-41.
8. Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation. 2010;89(7):779-95.
9. Sarmiento E, Rodriguez-Molina JJ, Fernandez-Yañez J, et al. IgG monitoring to identify the risk for development of infection in heart transplant recipients. Transpl Infect Dis. 2006;8(1):49-53.
10. Sarmiento E, Lanio N, Gallego A, et al. Immune monitoring of anti cytomegalovirus antibodies and risk of cytomegalovirus disease in heart transplantation. Int Immunopharmacol. 2009;9(6):649-52.
11. Bunde T, Kirchner A, Hoffmeister B, et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med. 2005;201(7):1031-6. (Pubitemid 40524670)
12. Sester U, Gärtner BC,Wilkens H, et al. Differences inCMV-specific Tcell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation. Am J Transplant. 2005;5(6):1483-9. (Pubitemid 40839442)
13. Gerna G, Lilleri D, Fornara C, et al. Monitoring of human cytomegalovirus-specific CD4 and CD8 T-cell immunity in patients receiving solid organ transplantation. Am J Transplant. 2006;6(10):2356-64. (Pubitemid 44359421)
14. Egli A, Binet I, Binggeli S, et al. Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients. J Transl Med. 2008;6:29.
15. Mattes FM, Vargas A, Kopycinski J, et al. Functional impairment of cytomegalovirus specific CD8 T cells predicts high-level replication after renal transplantation. Am J Transplant. 2008;8(5):990-9. (Pubitemid 351537766)
16. Gamadia LE, Remmerswaal EB, Weel JF, Bemelman F, van Lier RA, Ten Berge IJ. Primary immune responses to human CMV: Acritical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease. Blood. 2003;101(7):2686-92. (Pubitemid 36857631)
17. La Rosa C, Limaye AP, Krishnan A, Longmate J, Diamond DJ. Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease. J Infect Dis. 2007;195(5):633-44.
18. Opelz G, Döhler B, Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: A collaborative transplant study report. Am J Transplant. 2004;4(6):928-36. (Pubitemid 38745592)
19. Gerna G, Lilleri D, Chiesa A, et al. Virologic and immunologic monitoring of cytomegalovirus to guide preemptive therapy in solid-organ transplantation. Am J Transplant. 2011;11(11):2463-71.
20. Bunk S, Schaffert H, Schmid B, et al. Chlamydia pneumoniaeinduced memory CD4+ T-cell activation in human peripheral blood correlates with distinct antibody response patterns. Clin Vaccine Immunol. 2010;17(5):705-12.
21. Dasari V, Smith C, Zhong J, Scott G, Rawlinson W, Khanna R. Recombinant glycoprotein B vaccine formulation with Toll-like receptor 9 agonist and immune-stimulating complex induces specific immunity against multiple strains of cytomegalovirus. J Gen Virol. 2011;92:1021-31.
22. Sabbaj S, Pass RF, Goepfert PA, Pichon S. Glycoprotein B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women. J Infect Dis. 2011;203(11):1534-41.
23. Bonaros N, Mayer B, Schachner T, et al. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: A meta-analysis. Clin Transplant. 2008;22:89-97. (Pubitemid 351150008)
24. Peggs KS, Thomson K, Samuel E, et al. Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. Clin Infect Dis. 2011;52:49-57.
25. Engstrand M, Lidehall AK, Totterman TH, Herrman B, Eriksson BM, Korsgren O. Cellular responses to cytomegalovirus in immunosuppressed patients: Circulating CD8+ T cells recognizing CMVpp 65 are present but display functional impairment. Clin Exp Immunol. 2003;132(1):96-104. (Pubitemid 36418912)
26. Sester M, Sester U, Gärtner B, et al. Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virusinduced disease after renal transplantation. Transplantation. 2001;71(9):1287-94. (Pubitemid 32507149)
27. Gratama JW, Brooimans RA, van der Holt B, et al. Monitoring cytomegalovirus IE-1 and pp 65-specific CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations. Cytometry B Clin Cytom. 2008;74(4):211-20. (Pubitemid 352007318)
28. Kichner A, Hoffmeister B, Cherepnev-G G, et al. Dissection of the CMV specific T-cell response is required for optimized cardiac transplant monitoring. J Med Virol. 2008;80(9):1604-14.
29. Zhu J, Shearer GM, Marincola FM, et al. Discordant cellular and humoral immune responses to cytomegalovirus infection in healthy blood donors: Existence of a Th1-type dominant response. Int Immunol. 2001;13(6):785-90. (Pubitemid 32514703)
30. Manuel O, Pang XL, Humar A, et al. An assessment of donor-torecipient transmission patterns of human cytomegalovirus by analysis of viral genomic variants. J Infect Dis. 2009;199(11):1621-28.
31. Manuel O, Asberg A, Pang X, et al. Impact of genetic polymorphisms in cytomegalovirus glycoprotein B on outcomes in solidorgan transplant recipients with cytomegalovirus disease. Clin Infect Dis. 2009;49(8):1160-6.
32. Tu W, Potena L, Stepick-Biek P, et al. T-cell immunity to subclinical cytomegalovirus infection reduces cardiac allograft disease. Circulation. 2006;114(15):1608-15. (Pubitemid 44547431)
33. Nickel P, Bold G, Presber F, et al. High levels of CMV-IE-1- specific memory T cells are associated with less alloimmunity and improved renal allograft function. Transpl Immunol. 2009;20 (4):238-42.
34. Amir AL, D'Orsogna LJ, Roelen DL, et al. Allo-HLA reactivity of virus-specific memory T cells is common. Blood. 2010;115 (15):3146-57.
35. Ouwehand AJ, Balk AH, Baan CC, Vaessen LM, Jutte NH, Bos E, Claas FH, Weimar W, et al. Cytomegalovirus infection and allospecific cytotoxic activity of graft-infiltrating cells after heart transplantation. J Med Virol. 1994;42(2):175-81. (Pubitemid 24077561)
36. Ishibashi K, Tokumoto T, Shirakawa H, et al. Lack of antibodies against the antigen domain 2 epitope of cytomegalovirus (CMV) glycoprotein B is associated with CMV disease after renal transplantation in recipients having the same glycoprotein H serotypes as their donors. Transpl Infect Dis. 2011;13(3):318-23.